Stay updated with breaking news from Cellecti Adss. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
• Maximum Potential Dilution of Approximately 23.04%, Based on Share Capital of Cellectis as of September 30, 2022 NEW YORK, Jan. 04, 2023 -- Cellectis S.A. , a clinical-stage... | January 4, 2023
UCART22: anti-tumor activity observed in 60% of patients at DL3 using FCA lymphodepletionUCART123: 25% of patients at DL2 in the FCA arm achieved meaningful response; one patient experienced a... | December 13, 2022